Vaxart Faces Listing Rule Concerns

TL;DR

Vaxart's 8-K flags potential delisting issues - stock might be in trouble.

AI Summary

Vaxart, Inc. filed an 8-K on December 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard, or the transfer of a listing. The filing indicates potential issues with Vaxart's continued listing on the stock exchange.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could impact investor confidence and stock liquidity.

Risk Assessment

Risk Level: high — Filings related to delisting or failure to meet listing standards indicate significant financial or operational challenges that could lead to the stock being removed from major exchanges.

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• December 31, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• South San Francisco, California (location) — Business address

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
• $1.00 M — e Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth i
• $1.00 — a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecuti

Filing Documents

• vxrt20241231_8k.htm (8-K) — 27KB
• 0001437749-24-038599.txt ( ) — 157KB
• vxrt-20241231.xsd (EX-101.SCH) — 3KB
• vxrt-20241231_def.xml (EX-101.DEF) — 11KB
• vxrt-20241231_lab.xml (EX-101.LAB) — 15KB
• vxrt-20241231_pre.xml (EX-101.PRE) — 11KB
• vxrt20241231_8k_htm.xml (XML) — 3KB

01

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 2, 2024, Vaxart, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") for continued listing on The Nasdaq Capital Market. On December 31, 2024, Nasdaq notified the Company in writing (the "Extension Letter") that while the Company had not regained compliance with the Bid Price Requirement, it was eligible for an additional 180-day compliance period, or until June 30, 2025, to regain compliance with the Bid Price Requirement. Nasdaq's determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Requirement, and on the Company's written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company's common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until December 30, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until June 30, 2025 to regain compliance with the Bid Price Requirement. If at any time during this second 180-day period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq stated that th

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: December 31, 2024 By: /s/ Steven Lo Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR